Skip to main content

KRYS

Stock
Health Care
Biotechnology

Performance overview

KRYS Price
Price Chart

Forward-looking statistics

Beta
1.19
Risk
48.72%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

krystal biotech, inc. is using gene therapy to develop effective and novel treatments for skin diseases. our goal is to make a meaningful difference in the lives of underserved patient populations with debilitating skin diseases. we work to accomplish that through scientific innovation, operational excellence and believe that “nature operates in the shortest way possible”. (aristotle)

Company info

SectorHealth Care
IndustryBiotechnology
Employees208
Market cap$4.7B

Fundamentals

Enterprise value$3.4B
Revenue$333.4M
Revenue per employee
Profit margin37.18%
Debt to equity0.98

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)$4.16
Dividend per share
Revenue per share$11.61
Avg trading volume (30 day)$54M
Avg trading volume (10 day)$63M
Put-call ratio

Macro factor sensitivity

Growth+1.0
Credit+6.0
Liquidity-1.6
Inflation-2.7
Commodities+0.0
Interest Rates-2.0

Valuation

Dividend yield0.00%
PEG Ratio24.46
Price to sales12.40
P/E Ratio24.46
Enterprise Value to Revenue10.09
Price to book4.20

Upcoming events

Next earnings dayMay 6, 2025
Next dividend day
Ex. dividend day

News

KRYS Begins Dosing With Gene Therapy in Rare Eye Disease, Stock Up

Krystal Biotech climbs after dosing begins in a phase I/II trial for KB801, a gene therapy eye drop targeting neurotrophic keratitis.

Zacks Investment Research (July 10, 2025)
3 Promising Genomics Stocks to Keep an Eye On in 2025

Investors interested in the Genomics and Synthetic Biology theme should keep an eye on MGTX, BEAM and KRYS.

Zacks Investment Research (June 27, 2025)
Strength Seen in Krystal Biotech (KRYS): Can Its 4.2% Jump Turn into More Strength?

Krystal Biotech (KRYS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Zacks Investment Research (June 25, 2025)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free